this also supports the use of chlorambucil alone when treatment cost is a key consideration.
In this study, patients with primary gastric localization (a stratification criterion) apparently had better CR rate and EFS than those with MALT lymphoma at other sites, although this unplanned analysis must be interpreted with caution, especially since gastric lymphoma patients in the study more often had stage I disease. The study was underpowered to address the clinical relevance of different anatomic localizations.
In a single-arm phase II study of 57 patients [4, 5] , the Spanish GELTAMO group evaluated the combination of bendamustine and rituximab as first line systemic treatment of MALT lymphoma, showing an EFS at 7 years of 88%. Whilst these results appear better than those with chlorambucil-rituximab in IELSG-19, several unfavourable clinical features were less common in the GELTAMO study, including B symptoms, involvement of multiple extranodal sites, lymph nodes and bone marrow. This makes it hard to directly compare the results of the two studies.
There is no widely accepted prognostic index for MALT lymphoma. Using stepwise Cox regression, the IELSG-19 study database allowed the development of a specific prognostic tool for patients with MALT lymphoma. This demonstrated three features of greatest prognostic significance for EFS, namely age ≥70 years (HR 1.72), Ann Arbor stage III or IV (HR 1.79), and elevated LDH (HR 1.87). The prognostic index (named MALT-IPI) using these three parameters identified groups of low, intermediate and high risk (corresponding to the presence of 0, 1 or ≥2 of these factors, respectively). The 5-year EFS rates in these groups were 70%, 56% and 29%, respectively. The MALT-IPI also discriminated between patients of differing PFS, OS and cause-specific survival, was maintained across the 3 treatment arms and in both gastric and non-gastric patients. Histologic transformation during the IELSG-19 trial was reported in 10 patients. Notably, 7 of 10 were in the high risk group, and the other 3 in the intermediate risk group (P=<0.001).
An external validation set of 633 patients was studied by merging three independent cohorts of MALT lymphoma patients. This confirmed the MALT-IPI discriminating capacity in a large heterogeneous population of patients, irrespective of baseline features and treatment types, although overall outcomes in the validation cohort were worse than in IELSG-19. Cox Editorial www.impactjournals.com/oncotarget regression controlling for the cohort effect further attested the validity of the prognostic model. Interestingly, the prognostic validity of the MALT-IPI has subsequently been further confirmed in the GELTAMO study cohort treated with R-bendamustine [5] . The new, MALT-IPI, is a simple, accessible and effective tool to identify patients at risk of poor outcomes. It will help to define individual patient treatment approaches and trial designs for the future.
